TOP TEN perturbations for 39014_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39014_at
Selected probe(set): 203240_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39014_at (203240_at) across 6674 perturbations tested by GENEVESTIGATOR:
Langerhans cell histiocytosis study 1 / normal plasmocytoid dendritic cell sample
Relative Expression (log2-ratio):8.702643Number of Samples:7 / 3
| Experimental | Langerhans cell histiocytosis study 1 |
| Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity. | |
| Control | normal plasmocytoid dendritic cell sample |
| Normal plasmocytoid dendritic cells were isolated from peripheral blood of healthy adult donors. Plasmocytoid dendritic cells were defined as HLA-DR+ / CD45RAhi / CD11c- / BDCA2+ population. |
Langerhans cell histiocytosis study 1 / normal myeloid dendritic cell sample
Relative Expression (log2-ratio):6.995059Number of Samples:7 / 3
| Experimental | Langerhans cell histiocytosis study 1 |
| Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity. | |
| Control | normal myeloid dendritic cell sample |
| Normal myeloid dendritic cells were isolated from peripheral blood of healthy adult donors. Myeloid dendritic cells were defined as HLA-DR+ / CD11c + / BDCA1+ / BDCA3- population. |
colorectal cancer study 33 (carcinoma; colonic mucosa) / adjacent colon mucosa sample
Relative Expression (log2-ratio):-6.576808Number of Samples:5 / 5
| Experimental | colorectal cancer study 33 (carcinoma; colonic mucosa) |
| Colonic mucosa samples obtained by laser capture microdissection (LCM) from patients with colorectal carcinoma. | |
| Control | adjacent colon mucosa sample |
| Adjacent colon mucosa sample obtained by laser capture microdissection (LCM) from patients with colorectal cancer. |
colorectal cancer study 1 / normal colon tissue
Relative Expression (log2-ratio):-6.227927Number of Samples:6 / 6
| Experimental | colorectal cancer study 1 |
| Laser microdissected human colorectal cancer sample. | |
| Control | normal colon tissue |
| Laser microdissected human colonic epithelial cells sample. |
Barrett's esophagus study 3 / esophageal squamous cell carcinoma study 1
Relative Expression (log2-ratio):6.0205717Number of Samples:17 / 8
| Experimental | Barrett's esophagus study 3 |
| Esophageal epithelium samples from areas with Barrett's esophagus metaplasia which were recovered by laser capture microdissection. | |
| Control | esophageal squamous cell carcinoma study 1 |
| Esophageal squamous cell carcinoma (ESCC) biopsy samples from chemotherapy-naive patients with histological grading G1 (well differentiated) and UICC stage II and III, which undergone esophagectomy. |
colorectal cancer study 33 (carcinoma; colonic crypt) / adjacent colonic crypt epithelial cell sample
Relative Expression (log2-ratio):-5.6310644Number of Samples:5 / 5
| Experimental | colorectal cancer study 33 (carcinoma; colonic crypt) |
| Colonic crypt epithelial cell samples obtained by laser capture microdissection (LCM) from patients with colorectal carcinoma. | |
| Control | adjacent colonic crypt epithelial cell sample |
| Adjacent colonic crypt epithelial cells obtained by laser capture microdissection (LCM) from patients with colorectal cancer. |
rectal cancer study 2 (post; radiotherapy) / rectal cancer study 2 (post; chemoradiotherapy)
Relative Expression (log2-ratio):-5.6064663Number of Samples:4 / 4
| Experimental | rectal cancer study 2 (post; radiotherapy) |
| Tumor tissue samples obtained from the rectum of patients with rectal adenocarcinoma during a surgical resection, after treatment with short-course neoadjuvant radiotherapy (RT; 25Gy in 5 fractions). Samples were collected after 1 week of completing the therapy. Patients were selected for neoadjuvant RT based upon clinical and MRI staging features. Radiotherapy was CT planned, using a 3 field technique (posterior and two lateral fields), multileaf collimation, and with patients having a full bladder during the radiotherapy. Patients were proven to be medically fit for treatment (WHO PS 0-2), with no significant medical co-morbidities, in particular no history of unstable or severe ischemic heart disease, and adequate renal (creatinine clearance >50ml/min) and liver function (billirubin <1.5 ULN, transaminases and alkaline phosphatase <2x ULN ). The staging was performed by clinical examination high resolution MRI of the pelvis (under anaesthesia at the discretion of the treating surgeon), and CT scan of the thorax and abdomen. Tumor stage was assigned according to TMN classification of UICC 6th edition 2002. | |
| Control | rectal cancer study 2 (post; chemoradiotherapy) |
| Tumor tissue samples obtained from the rectum of patients with rectal adenocarcinoma during a surgical resection, after a treatment with neoadjuvant concurrent (5-FU-based) chemoradiotherapy (CRT). The regimen of the neoadjuvant CRT was as follows: folinic acid 20mg/m2, 5-flurouracil (5-FU), 350mg/m2 d1-5, and d29-33 with 45 Gy in 25 fractions. Samples were collected after 6-8 weeks of completing the therapy. Patients were selected for neoadjuvant CRT based upon clinical and MRI staging features. Radiotherapy was CT planned, using a 3 field technique (posterior and two lateral fields), multileaf collimation and with patients having a full bladder during the radiotherapy. Patients were proven to be medically fit for treatment (WHO PS 0-2), with no significant medical co-morbidities, in particular no history of unstable or severe ischemic heart disease, and adequate renal (creatinine clearance >50ml/min) and liver function (billirubin <1.5 ULN, transaminases and alkaline phosphatase <2x ULN ). The staging was performed by clinical examination high resolution MRI of the pelvis (under anaesthesia at the discretion of the treating surgeon), and CT scan of the thorax and abdomen. Tumor stage was assigned according to TMN classification of UICC 6th edition 2002. |
wound healing study 2 (ex vivo; DMSO) / normal skin tissue (ex vivo)
Relative Expression (log2-ratio):-5.564745Number of Samples:3 / 3
| Experimental | wound healing study 2 (ex vivo; DMSO) |
| Ex vivo skin samples obtained from healthy donors following reduction surgery of abdomen, and incubated in culture medium containing DMSO for 4 days. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. Skin was sliced into 1x10 mm slices and incubated in keratinocyte medium for four days with 1:1000 fold dilution of DMSO. The cultivation was performed in serum-free keratinocyte medium supplemented with transferrin, hEGF (0.15 ng/mL), 0.5 mg/mL hydrocortisone, gentamicin, amphotericin B, and epinephrine but without insulin. | |
| Control | normal skin tissue (ex vivo) |
| Normal skin samples obtained from healthy donors following reduction surgery of abdomen. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. |
rectal cancer study 2 (post; chemoradiotherapy) / rectal cancer study 2 (post; no therapy)
Relative Expression (log2-ratio):5.388794Number of Samples:4 / 2
| Experimental | rectal cancer study 2 (post; chemoradiotherapy) |
| Tumor tissue samples obtained from the rectum of patients with rectal adenocarcinoma during a surgical resection, after a treatment with neoadjuvant concurrent (5-FU-based) chemoradiotherapy (CRT). The regimen of the neoadjuvant CRT was as follows: folinic acid 20mg/m2, 5-flurouracil (5-FU), 350mg/m2 d1-5, and d29-33 with 45 Gy in 25 fractions. Samples were collected after 6-8 weeks of completing the therapy. Patients were selected for neoadjuvant CRT based upon clinical and MRI staging features. Radiotherapy was CT planned, using a 3 field technique (posterior and two lateral fields), multileaf collimation and with patients having a full bladder during the radiotherapy. Patients were proven to be medically fit for treatment (WHO PS 0-2), with no significant medical co-morbidities, in particular no history of unstable or severe ischemic heart disease, and adequate renal (creatinine clearance >50ml/min) and liver function (billirubin <1.5 ULN, transaminases and alkaline phosphatase <2x ULN ). The staging was performed by clinical examination high resolution MRI of the pelvis (under anaesthesia at the discretion of the treating surgeon), and CT scan of the thorax and abdomen. Tumor stage was assigned according to TMN classification of UICC 6th edition 2002. | |
| Control | rectal cancer study 2 (post; no therapy) |
| Tumor tissue samples obtained during a surgical resection from the rectum of untreated (no pre-operative treated) patients with rectal adenocarcinoma.Tumor stage was assigned according to TMN classification of UICC 6th edition 2002. |
pancreatic cancer study 3 (ipmc) / normal pancreas tissue
Relative Expression (log2-ratio):5.1684694Number of Samples:6 / 6
| Experimental | pancreatic cancer study 3 (ipmc) |
| Intraductal papillary mucinous carcinoma from patients with pancreatic cancer. | |
| Control | normal pancreas tissue |
| Normal human pancreatic tissue. |